MINE in the context of chemotherapy is an acronym for one of the chemotherapy regimens used for treatment of relapsed or refractory aggressive non-Hodgkin lymphoma and Hodgkin lymphoma.
Today this regimen is often combined with monoclonal antibody rituximab. In this case the regimen is called R-MINE or MINE-R.
The [R]-MINE regimen consists of: Rituximab - anti-CD20 monoclonal antibody that can kill both normal CD20-expressing B cells and malignant ones; Mesna to prevent the development of hemorrhagic cystitis which may otherwise result from ifosfamide administration; Ifosfamide - an alkylating antineoplastic agent from oxazafosforine group; Mitoxantrone - a synthetic anthracycline analogue (anthraquinone) that is able to intercalate DNA and thus prevent cell division (mitosis); Etoposide - a topoisomerase inhibitor.A phase II trial of mesna / ifosfamide, mitoxantrone and etoposide for refractory lymphomas Results of a salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP.
Dosing regimen Drug Dose Mode Days Rituximab 375 mg/m2 IV infusion Day 1 Mesna 1330 mg/m2 IV infusion over 1h together with ifosfamide, plus 500 mg PO 4h after ifosfamide Days 1-3 Ifosfamide 1330 mg/m2 IV infusion over 1h Days 1-3 Mitoxantrone 8 mg/m2 IV infusion Day 1 Etoposide 65 mg/m2 IV infusion over 1h Days 1-3
References